9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to t...

Full description

Bibliographic Details
Main Authors:	Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lu, Kyaw Thein, Benjamin S. Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang, Minghao Dang, Enyu Dai, Shaojun Zhang, Fengqi Nie, Shuangtao Zhao, Charles Guo, Ameer Hamza, Bogdan Czerniak, Chao Cheng, Arlene Siefker-Radtke, Krishna Bhat, Andrew Futreal, Guang Peng, Jennifer Wargo, Weiyi Peng, Humam Kadara, Jaffer Ajani, Charles Swanton, Kevin Litchfield, Jordi Rodon Ahnert, Jianjun Gao, Linghua Wang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-09-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-021-25894-9

id	doaj-f000b69e3fbd4f02bc414de145aab9e8
record_format	Article
spelling	doaj-f000b69e3fbd4f02bc414de145aab9e82021-09-26T11:45:19ZengNature Publishing GroupNature Communications2041-17232021-09-0112111910.1038/s41467-021-25894-99p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han0Guoliang Yang1Dapeng Hao2Yang Lu3Kyaw Thein4Benjamin S. Simpson5Jianfeng Chen6Ryan Sun7Omar Alhalabi8Ruiping Wang9Minghao Dang10Enyu Dai11Shaojun Zhang12Fengqi Nie13Shuangtao Zhao14Charles Guo15Ameer Hamza16Bogdan Czerniak17Chao Cheng18Arlene Siefker-Radtke19Krishna Bhat20Andrew Futreal21Guang Peng22Jennifer Wargo23Weiyi Peng24Humam Kadara25Jaffer Ajani26Charles Swanton27Kevin Litchfield28Jordi Rodon Ahnert29Jianjun Gao30Linghua Wang31Department of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer CenterTumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer InstituteDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Medicine, Epidemiology and Population Science, Baylor College of MedicineDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer CenterDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Biology and Biochemistry, University of HoustonDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer CenterDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer CenterCancer Evolution and Genome Instability Laboratory, The Francis Crick InstituteTumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer InstituteDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer CenterThe molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to therapy.https://doi.org/10.1038/s41467-021-25894-9
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Guangchun Han Guoliang Yang Dapeng Hao Yang Lu Kyaw Thein Benjamin S. Simpson Jianfeng Chen Ryan Sun Omar Alhalabi Ruiping Wang Minghao Dang Enyu Dai Shaojun Zhang Fengqi Nie Shuangtao Zhao Charles Guo Ameer Hamza Bogdan Czerniak Chao Cheng Arlene Siefker-Radtke Krishna Bhat Andrew Futreal Guang Peng Jennifer Wargo Weiyi Peng Humam Kadara Jaffer Ajani Charles Swanton Kevin Litchfield Jordi Rodon Ahnert Jianjun Gao Linghua Wang
spellingShingle	Guangchun Han Guoliang Yang Dapeng Hao Yang Lu Kyaw Thein Benjamin S. Simpson Jianfeng Chen Ryan Sun Omar Alhalabi Ruiping Wang Minghao Dang Enyu Dai Shaojun Zhang Fengqi Nie Shuangtao Zhao Charles Guo Ameer Hamza Bogdan Czerniak Chao Cheng Arlene Siefker-Radtke Krishna Bhat Andrew Futreal Guang Peng Jennifer Wargo Weiyi Peng Humam Kadara Jaffer Ajani Charles Swanton Kevin Litchfield Jordi Rodon Ahnert Jianjun Gao Linghua Wang 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy Nature Communications
author_facet	Guangchun Han Guoliang Yang Dapeng Hao Yang Lu Kyaw Thein Benjamin S. Simpson Jianfeng Chen Ryan Sun Omar Alhalabi Ruiping Wang Minghao Dang Enyu Dai Shaojun Zhang Fengqi Nie Shuangtao Zhao Charles Guo Ameer Hamza Bogdan Czerniak Chao Cheng Arlene Siefker-Radtke Krishna Bhat Andrew Futreal Guang Peng Jennifer Wargo Weiyi Peng Humam Kadara Jaffer Ajani Charles Swanton Kevin Litchfield Jordi Rodon Ahnert Jianjun Gao Linghua Wang
author_sort	Guangchun Han
title	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
title_short	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
title_full	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
title_fullStr	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
title_full_unstemmed	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
title_sort	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2021-09-01
description	The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to therapy.
url	https://doi.org/10.1038/s41467-021-25894-9
work_keys_str_mv	AT guangchunhan 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT guoliangyang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT dapenghao 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT yanglu 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT kyawthein 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT benjaminssimpson 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jianfengchen 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT ryansun 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT omaralhalabi 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT ruipingwang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT minghaodang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT enyudai 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT shaojunzhang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT fengqinie 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT shuangtaozhao 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT charlesguo 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT ameerhamza 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT bogdanczerniak 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT chaocheng 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT arlenesiefkerradtke 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT krishnabhat 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT andrewfutreal 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT guangpeng 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jenniferwargo 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT weiyipeng 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT humamkadara 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jafferajani 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT charlesswanton 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT kevinlitchfield 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jordirodonahnert 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT jianjungao 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy AT linghuawang 9p21lossconfersacoldtumorimmunemicroenvironmentandprimaryresistancetoimmunecheckpointtherapy
_version_	1716867822750007296

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Similar Items